Great review on the multi-pronged approach to KRAS mutated lung cancer.
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
Source :
https://www.sciencedirect.com/science/article/pii/S266637912030241XKRAS, an oncogenic driver in lung cancer, is known as an "undruggable" target Different strategies are under investigation to indirectly and directly target KRAS Clinical trials of small-molecule inhibitors report promising interim results KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer (NSCLC).
In the past, no therapies for targeting KRAS mutations was available. Now, the KRAS p.G12C mutation occurs in 13% of NSCLCs and in 1% to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRAS G12C. Recently clinical trial data confirmed that Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. Grade 3 or 4 treatment-related toxic effects occurred in 11.6% of the patients